Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDNNASDAQ:MNPRNASDAQ:ORGSNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$2.87-0.7%$3.24$2.00▼$5.54$171.86M0.08275,767 shs191,522 shsMNPRMonopar Therapeutics$35.10-11.0%$36.88$1.72▼$54.30$214.64M1.11359,271 shs24,247 shsORGSOrgenesis$1.95-6.3%$2.58$0.87▼$10.80$9.36M0.7210,273 shs3,083 shsTNXPTonix Pharmaceuticals$19.19+1.9%$18.15$6.76▼$672.00$123.49M1.63800,860 shs376,926 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals0.00%-12.69%-1.70%-36.06%+25.11%MNPRMonopar Therapeutics0.00%-11.79%+13.67%-23.57%+1,080.01%ORGSOrgenesis0.00%-16.13%+5.58%+50.72%+207,999,900.00%TNXPTonix Pharmaceuticals0.00%-5.80%+11.61%+57.79%-96.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals2.1944 of 5 stars3.52.00.00.03.61.70.0MNPRMonopar Therapeutics2.7756 of 5 stars3.45.00.00.02.22.50.0ORGSOrgenesisN/AN/AN/AN/AN/AN/AN/AN/ATNXPTonix Pharmaceuticals2.4772 of 5 stars3.52.00.00.02.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 3.00Buy$12.50335.54% UpsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3357.64% UpsideORGSOrgenesis 0.00N/AN/AN/ATNXPTonix Pharmaceuticals 3.00Buy$585.002,948.46% UpsideCurrent Analyst Ratings BreakdownLatest TNXP, MNPR, ELDN, and ORGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/19/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$76.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/AORGSOrgenesis$662K14.14N/AN/A($6.58) per share-0.30TNXPTonix Pharmaceuticals$10.09M12.23N/AN/A$5,751.80 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$116.54M-$2.36N/AN/AN/AN/A-189.99%-28.17%N/AMNPRMonopar Therapeutics-$8.40M-$3.60N/AN/AN/AN/A-107.21%-87.57%N/AORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%5/19/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$2,535.85N/AN/AN/A-1,197.86%-163.95%-118.88%5/12/2025 (Estimated)Latest TNXP, MNPR, ELDN, and ORGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 millionN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/A3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A6.536.53MNPRMonopar TherapeuticsN/A5.415.41ORGSOrgenesisN/A0.070.07TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%MNPRMonopar Therapeutics1.83%ORGSOrgenesis22.56%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals11.70%MNPRMonopar Therapeutics34.90%ORGSOrgenesis5.66%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionableORGSOrgenesis1504.80 million4.53 millionOptionableTNXPTonix Pharmaceuticals506.44 million1.87 millionNot OptionableTNXP, MNPR, ELDN, and ORGS HeadlinesRecent News About These CompaniesTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights | ...May 12 at 5:24 PM | gurufocus.comTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational HighlightsMay 12 at 5:24 PM | gurufocus.comTonix Pharmaceuticals Q1 2025 Earnings: EPS Loss of $2.84 Beats Estimates, Revenue at $2. ...May 12 at 5:24 PM | gurufocus.comTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational HighlightsMay 12 at 4:56 PM | investing.comTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational HighlightsMay 12 at 4:30 PM | globenewswire.comTonix Pharmaceuticals reports annual meeting resultsMay 10 at 9:34 PM | investing.comTonix Pharmaceuticals (TNXP) Projected to Post Earnings on MondayMay 10 at 1:45 AM | americanbankingnews.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.5% Higher - Here's WhyMay 7, 2025 | marketbeat.comTonix Pharmaceuticals (TNXP) Expected to Announce Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comGeode Capital Management LLC Purchases 1,855,907 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 6, 2025 | marketbeat.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest UpdateMay 5, 2025 | marketbeat.comTonix Pharmaceuticals Holding Corp Share Chat (TNXP.US)May 3, 2025 | lse.co.ukTonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual MeetingApril 29, 2025 | globenewswire.comTonix Pharmaceuticals culls cocaine intoxication trial amid enrollment woesApril 28, 2025 | fiercebiotech.comTonix Pharmaceuticals present data on potential Mpox vaccine TNX-801April 26, 2025 | markets.businessinsider.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 7.99%April 24, 2025 | aaii.comTonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025April 24, 2025 | globenewswire.comTonix Pharmaceuticals (TNXP) to Present at World Vaccine CongressApril 23, 2025 | gurufocus.comTonix Pharmaceuticals (TNXP) Falls Despite Market UpturnApril 23, 2025 | gurufocus.comTonix Pharmaceuticals to Present at World Vaccine Congress Washington 2025 on Novel Mpox VaccineApril 16, 2025 | quiverquant.comTonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025April 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNXP, MNPR, ELDN, and ORGS Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$2.87 -0.02 (-0.69%) Closing price 04:00 PM EasternExtended Trading$2.88 +0.00 (+0.17%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Monopar Therapeutics NASDAQ:MNPR$35.10 -4.32 (-10.96%) Closing price 04:00 PM EasternExtended Trading$35.50 +0.40 (+1.14%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Orgenesis NASDAQ:ORGS$1.95 -0.13 (-6.25%) As of 03:39 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Tonix Pharmaceuticals NASDAQ:TNXP$19.19 +0.36 (+1.91%) Closing price 04:00 PM EasternExtended Trading$19.16 -0.03 (-0.13%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
